
Gensight biologics: The stock soars after an update on production
Read also (CercleFinance.com) – GenSight Biologics soars on the Paris Stock Exchange on Monday morning after announcing that it had successfully produced a batch of its gene therapy intended for blind patients. The biopharmaceutical company reported this morning that its manufacturing partner in the United States had successfully produced a batch of Lumevoq, its investigational…